Independent validation of Dr. Goodenowe’s plasmalogen research

On July 24, the Alzheimer’s Association International Conference (AAIC) held a session titled “Gut-Liver-Brain Axis in Alzheimer’s Disease” where researchers from the multi-institutional Alzheimer’s Disease Metabolomics Consortium presented research results confirming Dr. Goodenowe’s original research findings linking low blood plasmalogen levels with increased risk of dementia. Dr. Goodenowe published his original findings in a 2007 peer-reviewed research publication titled “Peripheral Ethanolamine Plasmalogen Deficiency: A Logical Causal Factor in Alzheimer’s Disease and Dementia”. In addition to these original discoveries, Dr. Goodenowe subsequently developed and tested simplified blood plasmalogen indices in longitudinal patient cohorts and post-mortem pathology studies. These studies link blood plasmalogen deficiencies with a higher rate of cognitive decline, Alzheimer’s disease neuropathology, and higher mortality in elderly subjects, as presented at AAIC 2016.

The new research findings were presented by Dr. Mitchel A. Kling, MD, an associate professor of Psychiatry in the Perelman School of Medicine at the University of Pennsylvania and the Veterans Affairs Medical Center. Dr. Kling presented results from two independent patient populations: the first study included 1,547 subjects that have Alzheimer’s disease, mild cognitive impairment (MCI), or significant memory concerns (SMC), and subjects who were cognitively normal (CN) and who are enrolled in the Alzheimer’s Disease Neuroimaging Initiative; the second included 112 subjects from the Penn Memory Center, including those with Alzheimer’s, MCI, and CN. Dr. Kling and the Metabolomics Consortium team members observed that lower values of Dr. Goodenowe’s indices were associated with a higher likelihood of Alzheimer’s disease. A similar pattern was seen with MCI and CN associations. Additionally, some of the decreased plasmalogen levels were correlated with increased levels of the tau protein in the brain, a marker of Alzheimer’s disease.

“This research shows that an age-related deficiency of plasmalogens could lead to an increased risk of Alzheimer’s disease, because the liver cannot make enough of them,” said Dr. Kling. “Our findings provide renewed hope for the creation of new treatment and prevention approaches for Alzheimer’s disease.” Dr. Kling highlighted the importance of the research beyond just Alzheimer’s disease: “this research has a variety of interesting implications. For example, it highlights a potential relationship between conditions such as obesity and diabetes and Alzheimer’s–as the liver has to work harder to break down fatty acids over time. This could lead to the eventual destruction of the peroxisomes that create plasmalogens which thus, increases the risk of Alzheimer’s.”

Prodrome Sciences’ Dr. Goodenowe agrees that his plasmalogen indices are important in overall health and stated, “the results presented at AAIC further support our belief that most, if not all of the diseases associated with getting old are really complications arising from specific biochemical dysfunctions, called ‘prodromes’. It is also important to recognize that the plasmalogen deficiency reported here is a prodrome associated with overall neuronal degeneration and that complications arising from this overall neuronal weakening includes increased risk of not just dementia, but also stroke, Parkinson’s, and overall mortality. Effective disease prevention strategies begin with first identifying specific biochemical dysfunctions associated with disease such as these findings reported at AAIC. At Prodrome Sciences we are developing advanced diagnostic tools that deliver an accurate and thorough assessment of specific disease-causing biochemical abnormalities, or prodromes, and developing natural and safe bioprecursors that can be used in conjunction with our diagnostic tools such that optimal biochemical balances can be maintained throughout your lifespan. We believe that this is the true scientific method of disease prevention, increased longevity, and vitality.”

Dr. Dayan Goodenowe, Founder of Prodrome Sciences, is an expert on the biochemical basis of neurological diseases. After obtaining his PhD in Psychiatry and Neurochemistry in 1993, Dr. Goodenowe has dedicated his professional career to advancing biochemical research and the understanding of neurological diseases.

Share on facebook
Share on twitter
Share on linkedin
privacy
Your privacy is important to us.

To better protect your privacy, we provide this notice explaining our online information practices and the choices you can make about the way your information is collected and used. To make this notice easy to find, we make it available on our homepage and at every point where personally identifiable information may be requested.

Collection of Personal Information

When visiting drdayangoodenowe.com, the IP address used to access the site will be logged along with the dates and times of access. This information is purely used to analyze trends, administer the site, track users’ movement and gather broad demographic information for internal use. Most important, any recorded IP addresses are not linked to personally identifiable information.

Links to Third-Party Websites
We have included links on this site for your use and reference. We are not responsible for the privacy policies on these websites. You should be aware that the privacy policies of these sites may differ from our own.
Our Use of Google Analytics
The Dr. Dayan Goodenowe website uses the Google Analytics tool to measure traffic on the site and traffic to the site via our online advertising. This includes using certain Advertising Features, which enable Google Analytics to collect data about users via Google advertising cookies and identifiers, in addition to anonymous data collected through the standard Google Analytics implementation. These Advertising Features, which drdayangoodenowe.com may or may not be currently using, include:
  • Remarketing with Google Analytics. This allows us to display our ads to you as you search online for similar businesses.
  • Google Display Network Impression Reporting, which shows which of our ads users click on.
  • Google Analytics Demographics and Interest Reporting, which provides information about the age and gender of site users, along with the interests they express in their online travel and purchasing activities.
  • Integrated services that require Google Analytics to collect data via advertising cookies and identifiers.
We do not merge personally identifiable information with non-personally identifiable information collected through any Google advertising product or feature unless we have obtained robust notice of, and the user’s prior affirmative (i.e., opt-in) consent to, that merger. These Advertising Features, which drdayangoodenowe.com may or may not be currently using, include:
Opt Out

There are several ways to opt out of interest-based advertising and/or all tracking related to Google Analytics and its advertising features.
You can opt out of interest-based ads by Google through Ads Settings. When you opt out, you’ll still see ads but they may not be related to factors such as your interests, previous visits to other websites, or demographic details. Obtain instructions here.

The Network Advertising Initiative offers a free tool that allows users to opt out from receiving interest-based ads from some or all NAI participating member companies that use cookies on your computer browser to collect data for interest-based advertising. Find information about it here.

Website visitors can totally block Google Analytics with the Google Analytics opt-out browser add-on (click to download). This add-on instructs the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) running on websites to prohibit their information from being used by Google Analytics. Using the Google Analytics opt-out plug-in will not prevent site owners from using other tools to measure site analytics. Learn more about about the opt-out and how to properly install the browser add-on here.

Changes to this Privacy

Statement The contents of this statement may be altered at any time, at our discretion.

If you have any questions regarding the privacy policy of drdayangoodenowe.com then you may contact us at info@drdayangoodenowe.com

terms of use
Welcome to our website. If you continue to browse and use this website, you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern drdayangoodenowe.com’s relationship with you in relation to this website. If you disagree with any part of these terms and conditions, please do not use our website.

The term ‘drdayangoodenowe.com’ or ‘us’ or ‘we’ refers to the owner of the website whose registered office is:

40880 County Center Drive
Suite R
Temecula, CA 92591, USA

The term ‘you’ refers to the user or viewer of our website.

The use of this website is subject to the following terms of use:

The content of the pages of this website is for your general information and use only. It is subject to change without notice.

Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.

All trademarks reproduced in this website, which are not the property of, or licensed to the operator, are acknowledged on the website.

Unauthorized use of this website may give rise to a claim for damages and/or be a criminal offence.

From time to time, this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).

Your use of this website and any dispute arising out of such use of the website is subject to the laws of Canada and USA.

We use cookies to make this site as useful as possible. They are small text files we put in your browser to track usage of our site but they don’t tell us who you are. If you want to delete any cookies that are already on your computer, please refer to the instructions for your file management software to locate the file or directory that stores cookies.

This site is not a part of the Facebook website or Facebook Inc. Additionally, this site is not endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.